Surfactant and the neonatal lung.
Deficiency of pulmonary surfactant is responsible for a substantial proportion of the mortality and morbidity in infants born prematurely. Surfactant replacement therapy has been extensively investigated and has become a central part of neonatal intensive care in the UK over the last 3 years. Evidence for the efficacy of this treatment is provided as is a discussion of the different surfactant preparations available and different protocols for administration.
Gibson
A T
AT
Jessop Hospital for Women, Sheffield.
D002985:Clinical Protocols; D003362:Cost-Benefit Analysis; D005260:Female; D006801:Humans; D007231:Infant, Newborn; D008297:Male; D011663:Pulmonary Surfactants / Q000172:deficiency / Q000378:metabolism / Q000627:therapeutic use; D016032:Randomized Controlled Trials as Topic; D012127:Respiratory Distress Syndrome, Newborn / Q000188:drug therapy* / Q000401:mortality; D013501:Surface-Active Agents / Q000008:administration & dosage / Q000191:economics / Q000627:therapeutic use*
D011663:Pulmonary Surfactants; D013501:Surface-Active Agents